Abstract
In this review, we summarize and discuss recent studies on structural plasticity changes, particularly apoptosis, in the mammalian hippocampus in relation to stress and depression. Apoptosis continues to occur, yet with very low numbers, in the adult hippocampal dentate gyrus (DG) of various species. Stress and steroid exposure modulate the rate of apoptosis in the DG. Contrary to earlier studies, the impact of chronic stress on structural parameters of the hippocampus like cell number and volume, is rather modest, and requires prolonged and severe stress exposure before only small reductions ( < 10 %) become detectable. This does not exclude other structural parameters, like synaptic terminal structure, or dendritic arborization from being significantly altered in critical hippocampal subregions like the DG and/or CA3. Neither does it imply that the functional implications of the changes after stress are also modest. Of interest, most of the structural plasticity changes appear transient and are generally reversible after appropiate recovery periods, or following cessation or blockade of the stress or corticosteroid exposure. The temporary slowing down of both apoptosis and adult proliferation, i.e. the DG turnover, after chronic stress will affect the overall composition, average age and identity of DG cells, and will have considerable consequences for the connectivity, input and properties of the hippocampal circuit and thus for memory function. Modulation of apoptosis and neurogenesis, by drugs interfering with stress components like MR and/or GR, and/or mediators of the cell death cascade, may therefore provide important drug targets for the modulation of mood and memory.
Keywords: mineralocorticoid receptor (MR), HPA activity, corticosteroid, hippocampus, MRI
CNS & Neurological Disorders - Drug Targets
Title: Stress, Depression and Hippocampal Apoptosis
Volume: 5 Issue: 5
Author(s): Paul J. Lucassen, Vivi M. Heine, Marianne B. Muller, Eline M. van der Beek, Victor M. Wiegant, E. Ron De Kloet, Marian Joels, Eberhard Fuchs, Dick F. Swaab and Boldizsar Czeh
Affiliation:
Keywords: mineralocorticoid receptor (MR), HPA activity, corticosteroid, hippocampus, MRI
Abstract: In this review, we summarize and discuss recent studies on structural plasticity changes, particularly apoptosis, in the mammalian hippocampus in relation to stress and depression. Apoptosis continues to occur, yet with very low numbers, in the adult hippocampal dentate gyrus (DG) of various species. Stress and steroid exposure modulate the rate of apoptosis in the DG. Contrary to earlier studies, the impact of chronic stress on structural parameters of the hippocampus like cell number and volume, is rather modest, and requires prolonged and severe stress exposure before only small reductions ( < 10 %) become detectable. This does not exclude other structural parameters, like synaptic terminal structure, or dendritic arborization from being significantly altered in critical hippocampal subregions like the DG and/or CA3. Neither does it imply that the functional implications of the changes after stress are also modest. Of interest, most of the structural plasticity changes appear transient and are generally reversible after appropiate recovery periods, or following cessation or blockade of the stress or corticosteroid exposure. The temporary slowing down of both apoptosis and adult proliferation, i.e. the DG turnover, after chronic stress will affect the overall composition, average age and identity of DG cells, and will have considerable consequences for the connectivity, input and properties of the hippocampal circuit and thus for memory function. Modulation of apoptosis and neurogenesis, by drugs interfering with stress components like MR and/or GR, and/or mediators of the cell death cascade, may therefore provide important drug targets for the modulation of mood and memory.
Export Options
About this article
Cite this article as:
Lucassen J. Paul, Heine M. Vivi, Muller B. Marianne, van der Beek M. Eline, Wiegant M. Victor, Ron De Kloet E., Joels Marian, Fuchs Eberhard, Swaab F. Dick and Czeh Boldizsar, Stress, Depression and Hippocampal Apoptosis, CNS & Neurological Disorders - Drug Targets 2006; 5 (5) . https://dx.doi.org/10.2174/187152706778559273
DOI https://dx.doi.org/10.2174/187152706778559273 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Patents on Potential Drugs to Treat Alzheimer’s Disease: Special Emphasis on Small Peptides
Recent Patents on CNS Drug Discovery (Discontinued) PSEN1 Promoter Demethylation in Hyperhomocysteinemic TgCRND8 Mice is the Culprit, not the Consequence
Current Alzheimer Research Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Current Medicinal Chemistry Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Understanding the Obstacles to Uptake of Intervention Programmes and Services for Persons with Dementia
Current Alzheimer Research Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis
Current Alzheimer Research Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters Graphical Abstracts
Letters in Drug Design & Discovery Marine Natural Products as Acetylcholinesterase Inhibitor: Comparative Quantum Mechanics and Molecular Docking Study
Current Computer-Aided Drug Design 3D-QSAR and Molecular Docking Studies of Flavonoid Derivatives as Potent Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Mitogenomics: Recognizing the Significance of Mitochondrial Genomic Variation for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design α7 Nicotinic Acetylcholine Receptors in Alzheimer’s Disease: Neuroprotective, Neurotrophic or Both?
Current Drug Targets Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
Current Medicinal Chemistry Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology